Why "Zombie Cells" Build Up With Age: New Research Points to a Failing Cleanup System
Evidence review & editorial synthesis
One of the strangest features of aging is that the body gradually fills with cells that have stopped dividing but refuse to disappear. These senescent cells, sometimes called "zombie cells," can release inflammatory signals that disturb nearby tissue.
New research published in Nature Aging suggests one reason they accumulate: aging may damage the body's own system for clearing them. More intriguingly, the researchers were able to restore part of that system in old mice and reduce senescence-associated changes across several organs.
It is still preclinical. But it raises a much bigger possibility: what if future anti-aging treatments do not need to kill dysfunctional cells directly, but instead teach an aging body to clean them up again?
Aging may damage both the cells and the cleanup crew
Senescent cells are not dead. They are living cells that have entered a durable state in which they normally stop dividing. This can be useful. Senescence can prevent damaged cells from becoming cancerous and can temporarily assist wound healing and tissue remodeling.
The problem begins when these cells remain long after their useful role is over.
Persistent senescent cells can release a mixture of inflammatory cytokines, growth factors and tissue-remodeling molecules called the senescence-associated secretory phenotype, or SASP. Over time, that environment can promote inflammation, fibrosis and dysfunction in surrounding cells.
The immune system normally helps remove senescent cells. The new study identifies a mechanism that may explain why this process becomes less efficient with age.
The researchers focused on chaperone-mediated autophagy, or CMA, a selective form of cellular recycling in which particular proteins are delivered to lysosomes for destruction.
CMA activity declines with age. The new work suggests that this decline does more than make individual cells worse at housekeeping.
When CMA became defective in senescent cells, their metabolism and secretions changed. Their SASP became more capable of spreading senescence to neighboring cells and also suppressed CMA in macrophages, immune cells that help engulf unwanted cells.
The result is a feedback loop: aging weakens cellular cleanup, senescent cells become more disruptive, macrophages become worse at removing them, and still more senescent cells persist.
Scientists could partially switch the system back on
The study did not stop at identifying the pathway.
When researchers disabled CMA specifically in macrophages, old mice accumulated more senescent cells in tissues and cleared senescence more slowly during wound healing. That provides causal evidence that macrophage CMA is part of the body's normal senescent-cell disposal system.
Then the researchers tried the reverse experiment.
Eighteen-month-old mice received an experimental small molecule called CA77.1 that activates CMA. Treatment continued for five months, into an age roughly corresponding to late life for laboratory mice.
Compared with untreated old mice, treated animals showed reduced age-associated accumulation of senescence markers in adipose tissue, liver and lung. Several inflammatory and senescence-associated genes were also lower, and fibrotic changes were reduced in some tissues.
Macrophages taken from old mice could even recover phagocytic activity after CMA activation to levels comparable with macrophages from young mice in the experimental assay.
In a separate mouse model of pulmonary fibrosis, CMA activation also reduced disease severity.
That does not mean the mice were rejuvenated. The study did not show longer lifespan, younger appearance or reversal of whole-body biological age.
But it does show something important: one process that deteriorates with age was not simply an irreversible consequence of time. It could be pharmacologically pushed back toward a more youthful functional state.
Why restoring cleanup could be different from killing zombie cells
Most popular discussion of senescent cells focuses on senolytics, drugs designed to selectively kill them.
That strategy has produced striking animal results. In one landmark mouse experiment, genetic removal of p16-positive senescent cells delayed deterioration in the kidney, heart and fat and extended median lifespan. Another study found that senolytic treatment improved physical function in naturally aged mice and increased their remaining post-treatment survival.
Those results helped establish an important principle: senescent cells are not merely markers of aging. In some settings, they causally contribute to it.
The new CMA study suggests a potentially different strategy.
Instead of repeatedly finding and poisoning persistent senescent cells, future therapies might restore the surveillance system that young organisms already use to remove them.
If that proves possible in humans, it could be more physiological than simply eliminating every cell carrying a senescence marker. The biological challenge would be preserving useful temporary senescence while efficiently removing cells that persist and become harmful.
What could this mean if it eventually works in humans?
The most immediate possibility is not immortality. It is better tissue maintenance.
Persistent senescent cells and their inflammatory secretions have been linked to fibrosis, impaired regeneration and multiple age-related diseases. The new study already provides a direct example in mice: restoring CMA reduced senescence burden and improved pathology in experimental lung fibrosis.
A second possibility is healthier-looking and better-functioning tissue. Senescent cells accumulate in aging skin, where their secretions can contribute to chronic inflammation and breakdown of the extracellular matrix that supports skin structure. Future therapies that safely improve their clearance could therefore conceivably slow some components of visible skin aging. That remains a hypothesis, not a result of the current experiment.
Cancer is even more intriguing, and more complicated.
Senescence initially protects against cancer by preventing damaged cells from continuing to divide. But senescent cells that remain in aged tissues can create a chronic inflammatory and growth-promoting environment that may support later tumor development or progression.
In principle, better removal of persistent senescent cells could therefore reduce one component of the aged, cancer-promoting tissue environment. That is biologically plausible, but there is currently no evidence that CMA activation lowers cancer incidence in people.
The broadest possibility is improved healthspan. If aging tissues deteriorate partly because damaged cells accumulate faster than the immune system can remove them, restoring clearance might influence several organs at once rather than treating each downstream disease separately.
That is the vision. It is also where the evidence becomes increasingly speculative.
The bigger shift may be how we think about aging
The study points toward a subtle change in perspective.
Aging is often imagined as an unavoidable accumulation of damage. But organisms also possess maintenance systems designed to repair, recycle and remove damage. Some of those systems themselves deteriorate with age.
That distinction matters because a failing maintenance system is potentially a therapeutic target.
The researchers have not shown that people can be made younger by activating CMA. Human senescent-cell biology is more complex than a mouse model, CA77.1 is experimental, and altering a pathway involved in protein recycling and immune function could carry risks that only clinical studies can reveal.
But the experiment demonstrates a useful principle: an age-related loss of cellular housekeeping can be manipulated, and doing so can reduce the burden of one of aging's most studied forms of cellular damage.
If future research can translate that principle safely to humans, the goal may not simply be to remove more zombie cells.
It may be to restore some of the biological machinery that once prevented them from accumulating in the first place.
Scientific References & Further Reading
- Anchor Study: “Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells.” (Sereda R, Lindenau K, Diaz A, et al. Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells. Nature Aging. 2026. doi:10.1038/s43587-026-01240-w.)
- Senescent Cell Immune Surveillance: “Immune surveillance of senescent cells in aging and disease.” (Majewska J, Krizhanovsky V. Immune surveillance of senescent cells in aging and disease. Nature Aging. 2025;5:1415-1424.)
- Healthspan and Lifespan: “Naturally occurring p16Ink4a-positive cells shorten healthy lifespan.” (Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. 2016;530:184-189. doi:10.1038/nature16932.)
- Senolytic Intervention: “Senolytics improve physical function and increase lifespan in old age.” (Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018;24:1246-1256. doi:10.1038/s41591-018-0092-9.)
- Cancer Context: “Stromal senescence contributes to age-related increases in cancer.” (Ye J, Melam A, Stewart SA. Stromal senescence contributes to age-related increases in cancer. Nature Reviews Cancer. 2025;25:781-800. doi:10.1038/s41568-025-00840-9.)
- Skin Aging Context: “Senescence as a molecular target in skin aging and disease.” (Thau H, Gerjol BP, Hahn K, et al. Senescence as a molecular target in skin aging and disease. Ageing Research Reviews. 2025;105:102686. doi:10.1016/j.arr.2025.102686.)
Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for diagnosis, treatment, or individualized medical care.

